Ohio State Clinical Trial Uses New Drug to Target Cancer Cells
By targeting a specific protein, Ohio State researchers hope to provide more effective treatments for patients with hard-to-cure cancers.
Researchers at the OSUCCC – James have developed a drug that acts as an inhibitor for PRMT5, a protein that is over-expressed in many aggressive cancers, including lung cancer, triple-negative breast cancer, acute myeloid leukemia and glioblastoma.
The team is currently conducting a clinical trial that uses the drug to target PRMT5, which is only present in cancer cells.
“It’s a real exciting target because it’s not expressed in normal human tissues, only in cancer cells. So the toxicity profile can be really well controlled,” says Robert Baiocchi, MD, PhD.